Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672016 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
A Phase 3 study of Female Contraception, sponsored by Mylan Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT06672016 is a Phase 3 study of Female Contraception that is actively recruiting participants, run by Mylan Pharmaceuticals. The registered enrollment target is 1,500 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06672016, a Phase 3 study of Female Contraception, is actively recruiting participants, sponsored by Mylan Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Conditions Studied
Interventions
- DRUG Transdermal system containing progestin
Study Locations (20)
Florida
- AMR Fort Myers - Fort Myers
- Altus Research - Lake Worth
- OB GYN Associates of Mid Florida P.A. - Leesburg
- Genoma Research Group - Miami
- Spotlight Research Center - Miami
- New Age Med Research Corp - Miami
- Sensible Healthcare, LLC - Ocoee
- Innovation Medical Research Center - Palmetto Bay
- Clinical Research Center of Florida - Pompano Beach
Alabama
- Alabama Clinical Therapeutics, LLC - Birmingham
- SEC Clinical Research - Dothan
- AMR Mobile - Mobile
- Velocity Clinical Research - Mobile
California
- Velocity Clinical Research Santa Ana - Huntington Park
- Essential Access Health - Los Angeles
- Women's Health Care Research Corp - San Diego
- WR-Medical Center For Clinical Research - San Diego
Arizona
- Velocity Clinical Research - Phoenix
- Precision Trials - Phoenix
Georgia
- CenExel iResearch LLC - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06672016
The ClinicalTrials.gov registry entry for NCT06672016 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Female Contraception appearing as the primary indexed condition, and to 1 intervention - of which Transdermal system containing progestin is the first listed.
NCT06672016 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06672016 about?
NCT06672016 is a clinical study titled "Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential". The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a trans...
What is the current status of trial NCT06672016?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2025-01-13. Estimated completion is 2027-04.
What conditions does trial NCT06672016 study?
This clinical trial studies the following conditions: Female Contraception.
What interventions are being tested in trial NCT06672016?
The interventions under investigation include: Transdermal system containing progestin (DRUG).
Who is sponsoring clinical trial NCT06672016?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672016 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Female Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.